The webcast begins at 4:30 p.m. Eastern time, featuring a review of recent financial outcomes and a dedicated session for questions and answers. Interested participants can access the event through the company’s investor relations portal or via a direct link provided by the firm. Castle Biosciences recommends logging in at least 10 minutes prior to the start to ensure connectivity. For those unable to attend the live presentation, a replay will be available on the company website shortly after the broadcast concludes.

Based in Friendswood, Texas, Castle Biosciences continues to focus on developing molecular tests for dermatologic and gastroenterological conditions. The company’s portfolio, which includes products like DecisionDx-Melanoma and TissueCypher, aims to provide clinicians with actionable data to refine patient care plans and treatment strategies.